₹145 to ₹1,397: What made this pharma stock deliver 861% returns in less than 3 yrs?

Synopsis: Wockhardt’s remarkable turnaround, rising over 861 percent after a decade-long 93 percent decline, is driven by breakthrough antibiotic Zaynich, a strong biotech portfolio, global approvals, and margin recovery, showing how innovation and execution can revive a struggling pharma company.

Wockhardt, once ranked among India’s top pharmaceutical companies, has delivered a stunning revival. After a brutal near 93 percent collapse in its stock price over a decade, the company has surprised investors with a sharp rebound, soaring over 861 percent in the past two years, marking one of the most dramatic turnarounds in the sector. What triggered this remarkable turnaround?

Wockhardt Ltd, with a market capitalization of Rs. 22,700.16 crore, closed at Rs. 1,397 per equity share, up by 0.68 percent from its previous day’s close price of Rs. 1,387.60 per equity share.

Wockhardt Limited is a Mumbai-based pharmaceutical and biotech company founded in 1967, operating across India, the US, Europe, and other global markets. It manufactures pharmaceuticals and chemicals, with a strong focus on novel antibiotics such as ZAYNICH, MIQNAF, FOVISCU, and ODRATE, alongside insulin products, vaccines like Biovac-B, and biologics including Wepox and Wosulin.

Wockhardt Ltd has delivered multiple returns across multiple timeframes, with a 3-month return of 1.48 percent, a 6-month return of -23.44 percent, and a 1-year return of 2.06 percent. The stock fell sharply from a high of Rs. 1,998.60 in March 2013 to Rs. 145.35 in March 2023, resulting in a loss of 92.7 percent over 10 years. However, since March 2023, it has rebounded strongly, rising from Rs. 145.35 to around Rs. 1,397, which means a gain of nearly 861.12 percent in less than three years.

The Fall of Wockhardt

Two decades ago, Wockhardt, led by founder Habil Khorakiwala, was a shining star in India’s pharma industry. The company expanded aggressively through acquisitions across India, France, and the UK. By 2004, Khorakiwala ranked 19th among India’s richest, and Wockhardt was among the top 10 pharma firms in the country.

However, this rapid expansion came at a cost. Debt-fueled growth eventually strained finances, and by 2009, the company defaulted on its debt obligations. Ratings agencies downgraded the company, and revenues stagnated while losses and negative cash flow persisted for the next decade. Yet, amid this turmoil, the company never stopped innovating.

Discovery of Zaynich

In 2011, Wockhardt began development of Zaynich, an antibiotic targeting multidrug resistant infections. The breakthrough came from a case of a young cancer patient in the US battling a chronic infection resistant to conventional treatment. Compassionate use of Zaynich cured the patient in just four weeks.

By March 2025, 51 patients had received Zaynich under compassionate use, with a reported success rate exceeding 95 percent. Clinical trials showed the drug’s superiority which is 20 percent better than Meropenem in phase 3 trials. Its susceptibility breakpoint of 64 mg/L, compared to 2–8 mg/L for recent antibiotics, positioned Zaynich as a rare, highly effective therapy.

According to Khorakiwala, Zaynich is one of the few novel antibiotics discovered globally in the last 50 years, with a US FDA Qualified Infectious Disease Product status, fast-track review, and market exclusivity for five years.

What is Zaynich?

Zaynich is a new, advanced antibiotic developed by Wockhardt to treat serious, life-threatening bacterial infections that no longer respond to commonly used antibiotics due to antimicrobial resistance. It works by combining a powerful antibiotic with a novel resistance-breaking agent, allowing it to kill multi-drug-resistant Gram-negative bacteria. Zaynich is used mainly in hospital and ICU settings to cure severe infections such as hospital-acquired and ventilator-associated pneumonia, bloodstream infections (sepsis), complicated urinary tract infections, and serious abdominal infections, where existing medicines often fail.

Market Opportunity

Wockhardt estimates the total addressable market (TAM) for Zaynich across the US, Europe, and India at nearly $9 billion. India represents 11.1 lakh cases, while the US 1.6 lakh cases and Europe 2.1 lakh cases.

In FY25, Wockhardt already had a strong geographic mix: UK contributed 39 percent of revenue, India contributed 22 percent, EU contributed 12 percent, U.S contributed 3 percent and rest of world contributed 24 percent. With Zaynich positioned as a high-value therapy for life-threatening infections, its revenue potential is significant despite limited volume.

Global Regulatory Milestones

Zaynich’s NDA (New Drug Application) was accepted by the US FDA in September 2025, marking a historic moment for India as it is the first approval for a new chemical entity (NCE) from an Indian pharma company. The drug received fast-track designation, signalling global urgency and recognition of its medical value.

The European Medicines Agency (EMA) granted accelerated assessment for WCK 5222 (Zidebactam + Cefepime), enabling potential pan-European approval for severe, multidrug-resistant infections. 

Preparing for Commercial Success

Wockhardt has readied its commercial infrastructure. In India, a field force targets 80,000–100,000 patients within three years. Globally, the company plans either in-house commercialization or licensing deals. The US market will be supplied from European facilities, while India and emerging markets will rely on domestic production.

Beyond Zaynich, Wockhardt’s Mikanef (respiratory infections) and diabetes biologics portfolio (market ~Rs 27,000 crore) will further contribute to revenue growth. Management aims to double total revenue over the next three years, with biotechnology segment growth of 20–25 percent aided by capacity expansion.

Valuation

Despite the hype, Wockhardt now trades at an EV/EBITDA of 50x, highlighting the importance of commercial execution. The company now trades at a P/E of 413x, significantly higher than the industry average of 29.6x, highlighting lofty expectations. Zaynich approvals, launch strategy, and adoption across markets will determine whether the company can sustain its growth trajectory and translate scientific breakthroughs into long-term shareholder value.

Q2 Financial Performance

In Q2FY26, the company reported revenue of Rs. 782 crore, slightly lower than Rs. 809 crore in Q2FY25, marking a YoY decline of 3.2 percent, but up 6 percent QoQ from Rs. 738 crore in Q1FY26.

Profitability showed a strong turnaround, with EBITDA rising to Rs. 178 crore, up 61 percent YoY from Rs. 110 crore and 147 percent QoQ from Rs. 72 crore. The company posted a net profit of Rs. 82 crore, reversing losses of -Rs. 16 crore YoY and -Rs. 108 crore QoQ, highlighting significant margin recovery and operational improvement.

Shareholding Pattern

As of September 2025, the company’s shareholding is led by promoters with a 49.09 percent stake, followed by institutional investors, with FIIs holding 7.1 percent and DIIs 11 percent. The government owns 0.02 percent, while the public holds 32.79 percent of the shares. Notably, renowned investor Rekha Junjunwala has a 1.75 percent stake in the company, reflecting confidence from a seasoned market participant.

Conclusion

Wockhardt’s story shows how innovation and focus can turn around even a struggling company. Breakthrough drugs like Zaynich have driven its revival, but the company’s future success will depend on how well it can turn these scientific advances into steady business growth. The journey highlights the importance of careful planning, strong research, and execution in the pharma industry.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post ₹145 to ₹1,397: What made this pharma stock deliver 861% returns in less than 3 yrs? appeared first on Trade Brains.